"Pulmonary embolism is fundamentally a cardiovascular disease, where restoration of hemodynamic stability, beyond simple clot removal, is the key determinant of patient recovery,” one researcher explained.
Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.
The past four years have witnessed major advancements in medical science’s drive to unravel the complexities of the human immune system. We have the COVID-19 pandemic to thank for much of the progress.
